Where will Blueprint Medicines Stock Be In 1 Year?

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating https://day-trading.info/ system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.

Only 3.42% of the stock of Blueprint Medicines is held by insiders. Blueprint Medicines does not have a long track record of dividend growth. Short interest in Blueprint Medicines has recently increased by 1.84%, indicating that investor sentiment is decreasing. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

Blueprint Medicines Historical Prices

Kate Haviland has an approval rating of 100% among the company’s employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.

According to 16 Wall Street analysts that have issued a 1 year BPMC price target, the average BPMC price target is $75.44, with the highest BPMC stock price forecast at $114.00 and the lowest BPMC stock price forecast at $38.00. Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank.

Download StockLight

This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies. Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically during the Regular Trading Hours. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. Discuss news and analysts’ price predictions with the investor community.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. On average, Wall Street analysts predict that Blueprint Medicines’s share price could reach $75.44 by Feb 28, 2024.

According to 25 stock analysts, the average 12-month stock price forecast for BPMC stock is $70.02, which predicts an increase of 55.63%. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction. Blueprint Medicines announces better-than-expected financial performance in fourth-quarter and full-year 2022. Live educational sessions using site features to explore today’s markets. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.

NASDAQ: BPMC

“Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”). These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser.

All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. The Score for BPMC is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.

NASDAQ: BPMCBlueprint Medicines Corp Stock Forecast, Predictions & Price Target

Over the last year, Blueprint Medicines Corp has hit prices as high as $79.40 and as low as $37.82. Blueprint Medicines Corp is up 5.8% from its previous closing price of $43.82. One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough. Since inception in 1978, the nonprofit AAII has helped over 2 million individuals build their investment wealth through programs of education, publications, software and grassroots meetings.

The company’s average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating. Roche Holding AG said Tuesday that it will invest and codevelop a lung-cancer drug with U.S. company Blueprint Medicines Corp. The two companies will develop pralsetinib, a therapy for people with RET-altered nonsmall cell… Shares of Blueprint Medicines Corp. gained 8.3% reymount investment ltd review in premarket trading on Tuesday, the day after the company announced a deal with Roche Holding AG to develop and commercialize pralsetinib, an investigational cancer drug. On average, 9 Wall Street analysts forecast BPMC’s earnings for 2024 to be -$323,911,078, with the lowest BPMC earnings forecast at -$537,452,456, and the highest BPMC earnings forecast at -$147,559,491.

Blueprint’s early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA. Earnings results from Biogen and updates from EBS are the key highlights from the biotech sector during the past week. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. We don’t racially profile, harass, terrorize, or unnecessarily kill Black people should be the police accountability blueprint. The flight marked the start of a three-month trial, during which it will ferry chemo drugs and other supplies between sites in a remote part of England. A recent paper in the Stanford Technology Law Review examines how compassionate medical release decisions for incarcerated people were guided by a practice that lead to systemic underdiagnosis and under-staging of CKD in Black people.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

year Blueprint Medicines price prediction

Our research is based on sources that we believe to be reliable. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Past performance is not a guarantee of future results, and a loss of original capital may occur.

You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. The average analyst rating for BPMC stock from 25 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months. Blueprint Medicines exhibits a price/sales ratio which is less than the industry average for drugs stocks listed on the NASDAQ.

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing selling pressure, which indicates risk of future bearish movement. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

• The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
• In 2025, BPMC is forecast to generate -$171,552,904 in earnings, with the lowest earnings forecast at -$451,076,168 and the highest earnings forecast at $54,585,015.
• Based on 17 analysts offering ratings for Blueprint Medicines Corp.

This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.